More than two years have passed since Merck discontinued a high-profile cancer vaccine trial, yet the underlying scientific questions persist without resolution. The experimental treatment, known as mRNA-5671 or V941, represented Moderna’s effort to target mutations in the KRAS gene—a genetic driver behind some of the most aggressive malignancies.
The vaccine was designed as a tetravalent therapy, meaning it aimed at four specific KRAS mutations simultaneously: G12D, G12V, G13D, and G12C. This approach acknowledged that KRAS mutations are not a single defect but a family of genetic errors, making broad coverage essential. Moderna’s strategy was to train the immune system to recognize these mutant proteins and attack tumors that had developed mechanisms to evade detection.
The clinical trial, registered under identifier NCT03948763, was terminated by Merck in 2021 and officially concluded on August 25, 2022. The consequences of this decision extend beyond a single failed experiment.
For patients with pancreatic adenocarcinoma, where the five-year survival rate remains in the single digits, the loss of a targeted vaccine candidate eliminated one of the few potential options in a treatment landscape with limited choices. Similarly, for colorectal cancer patients with microsatellite instability, the setback reinforced a known challenge: the immune system often overlooks these tumors unless compelled to engage. Despite the trial’s termination, the concept of targeting KRAS has not disappeared.
Other pharmaceutical companies continue to pursue this gene. Amgen has developed a drug targeting the G12C mutation, and Mirati has another similar small-molecule inhibitor.
These are not vaccines but demonstrate that KRAS is no longer considered an undruggable target. Moderna itself maintains other cancer vaccine programs, including one for melanoma. The mRNA platform that enabled COVID-19 vaccines was always intended for oncology applications; mRNA-5671 was merely the first attempt at a particularly difficult target.
The primary legacy of this trial’s failure is caution within the drug development community. Researchers now recognize that creating a vaccine against KRAS is more complex than initial theories suggested.
The mutations reside inside cells rather than on their surfaces, requiring the immune system to recognize intracellular material as a threat—a significantly more challenging task than identifying viral spike proteins. Observers are now watching whether any company will test a combination approach, pairing a KRAS vaccine with a checkpoint inhibitor or small-molecule inhibitor. The terminated trial did not explore such combinations; it tested the vaccine alone or with Merck’s Keytruda. Full results were never published, and that silence itself provides information.
Currently, mRNA-5671 remains listed as terminated on clinicaltrials.gov. Patients who might have enrolled have returned to standard treatments. The KRAS problem persists, and the idea that a vaccine could contribute to a solution remains alive, though the science is still early and the setbacks are genuine.
